statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Carisma Therapeutics Announces Changes to its Board of Directors

Carisma Therapeutics Announces Changes to its Board of Directors Carisma Therapeutics Announces Changes to its Board of Directors PR Newswire PHILADELPHIA, July 1, 2024 Appointment of David Scadden...

Why Are Carisma Therapeutics Shares Surging Friday?

Carisma Therapeutics Inc. (NASDAQ: CARM) shares are trading higher on Friday following the company's announcement of a significant development in its collaboration with Moderna.
read more...

Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna

Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna Carisma Therapeutics Announces Nomination of First...

Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors

Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the...

Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum

Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum PR Newswire PHILADELPHIA, June 25, 2024...

Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders

Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders PR Newswire PHILADELPHIA, June 13, 2024...

Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference

Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference PR Newswire PHILADELPHIA, May 30...

Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte

Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical...

Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights PR...

Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024

Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024 Carisma Therapeutics Presents Preclinical Proof of...

Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in April 2016 and is headquartered in Philadelphia, PA.

Volume	186,516.00
52-Wk High	$7.14
52-Wk Low	$0.99

CARM Carisma Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals